InnoCare reported positive Phase III results for fadeucravacitinib (ICP-488) in moderate-to-severe plaque psoriasis, meeting the primary endpoint with significant efficacy and a favorable safety profile.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
InnoCare Pharma has reported positive topline results from its registrational Phase III clinical trial evaluating fadeucravacitinib (ICP-488), an investigational oral TYK2 (tyrosine kinase 2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The study met its primary endpoint with statistically significant and clinically meaningful improvement over placebo while also achieving multiple secondary efficacy endpoints. The company said the safety profile remained consistent with previous clinical studies, with no new safety signals identified.
Phase III Trial Achieves Primary and Secondary Endpoints
The pivotal Phase III study was a randomized, double-blind, placebo-controlled, multicenter registrational trial assessing the efficacy, safety, and tolerability of fadeucravacitinib in patients with moderate-to-severe plaque psoriasis.
According to the topline findings, treatment with fadeucravacitinib produced statistically significant improvements in the primary efficacy endpoint compared with placebo. The investigational therapy also met several predefined secondary endpoints, demonstrating consistent clinical benefit across multiple measures of disease activity.
Although the company did not disclose detailed efficacy data, it confirmed that comprehensive clinical and safety results will be presented at upcoming international scientific congresses and published in a peer-reviewed medical journal.
Safety findings were consistent with the drug’s established profile from earlier clinical studies, and investigators reported no new safety concerns during the trial.
Oral TYK2 Inhibitor Targets Key Inflammatory Pathways
Fadeucravacitinib is a potent, selective oral TYK2 allosteric inhibitor that binds to the enzyme’s JH2 regulatory domain. This mechanism selectively inhibits signaling through inflammatory cytokine pathways, including interleukin (IL)-23, IL-12, and type I interferons, which play central roles in the pathogenesis of psoriasis and several autoimmune diseases.
By selectively modulating TYK2 signaling rather than broadly suppressing the JAK family of kinases, the therapy is intended to reduce inflammatory activity while maintaining a favorable safety profile.
Beyond psoriasis, InnoCare is also developing fadeucravacitinib for additional autoimmune disorders, including cutaneous lupus erythematosus (CLE) and Sjögren’s syndrome, potentially expanding its clinical applications.
Psoriasis Continues to Drive Demand for New Oral Therapies
Psoriasis is a chronic immune-mediated inflammatory skin disease characterized by erythematous plaques, scaling, and persistent systemic inflammation. The condition can substantially impair quality of life through physical symptoms, psychological distress, and long-term disease burden.
While biologic therapies have transformed treatment outcomes for many patients, oral treatment options remain limited, creating ongoing demand for effective and convenient therapies.
InnoCare cited estimates projecting the global psoriasis treatment market to reach approximately $57.7 billion by 2032. In China alone, recent reports indicate that approximately 8.66 million people are living with psoriasis, with disease prevalence continuing to increase.
Clinical Implications
Dr. Jasmine Cui, Co-founder, Chairwoman, and Chief Executive Officer of InnoCare Pharma, said the positive Phase III outcome represents an important milestone for the company’s autoimmune disease portfolio. She noted that many patients with psoriasis continue to require additional oral treatment options and said the company plans to complete the ongoing Phase III program while advancing regulatory submissions.
Path Forward
The successful Phase III results position fadeucravacitinib for regulatory filing as a potential new oral treatment for moderate-to-severe plaque psoriasis. InnoCare plans to complete the registrational development program and submit the therapy for regulatory review while continuing clinical development across multiple autoimmune diseases, including cutaneous lupus erythematosus and Sjögren’s syndrome. Additional efficacy and safety analyses from the Phase III trial are expected to be shared through scientific presentations and peer-reviewed publications in the coming months.
Reference
About the Writer
Meghana Jinka (LinkedIn) is a Pharm.D graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.